Metachronous primary melanoma and lymphoma

Annals of Plastic Surgery

Volumn 64, Issue 2, 2010, Pages 229-232

  McIntosh, Bryan C ^a   Ariyan, Stephan ^b   Esche, Gretchen ^c   Zelterman, Daniel ^d   Narayan, Deepak ^a  

^a NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

^d YALE UNIVERSITY   (United States)

Author keywords

Cutaneous melanoma; Metachronous primary neoplasm; Non Hodgkin lymphoma

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; B CELL LYMPHOMA; FEMALE; HUMAN; MALE; MELANOMA; MIDDLE AGED; MORTALITY; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; SECOND CANCER; SKIN TUMOR; SURVIVAL; UNITED STATES;

ADOLESCENT; ADULT; CONNECTICUT; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MELANOMA; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASMS, SECOND PRIMARY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 77649121558     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/SAP.0b013e3181a13dbf     Document Type: Article

References (26)

1. Peller S. Metachronous multiple malignancies in 5876 cancer patients. Am J Hygiene. 1941;34:1-11.
2. Moertel CG, Dockerty MB, Baggenstoss AH. Multiple primary malignant neoplasms. Cancer. 1961;14:221-248.
3. Ariyan S, Poo WJ, Bolognia J, et al. Multiple primary melanomas: data and significance. Plast Reconstr Surg. 1995;96:1384-1389.
4. Schmid-Wendtner MH, Baumert J, Wendtner CM, et al. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol. 2001;145:981-985.
5. Swerdlow AJ, Storm HH, Sasieni PD. Risk of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer. 1995;61:773-779.
6. Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer. 2003;97:639-643.
7. Nashan D, Kocer B, Schiller M, et al. Significant risk of second melanoma in patients with a history of melanoma but no further predisposing factors. Dermatology. 2003;206:76-77.
8. Riou JP, Ariyan S, Brandow KR, et al. The association between melanoma, lymphoma, and other primary neoplasms. Arch Surg. 1995;130:1056-1061.
9. Goggins WB, Finkelstein DM, Tsao H. Evidence for an association between cutaneous melanoma and non-Hodgkin's lymphoma. Cancer. 2001;91:874-880.
10. Travis LB, Curtis RE, Boice JD Jr, et al. Second cancers following non- Hodgkin's lymphoma. Cancer. 1991;67:2002-2009.
11. Dong C, Hemminki K. Second primary neoplasms among 53159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer. 2001;85:997-1005.
12. Adami J, Frisch M, Yuen J, et al. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ. 1995;310:1491-1495.
13. Brennan P, Scélo G, Hemminki K, et al. Second primary cancers among 109000 cases of non-Hodgkin's lymphoma. Br J Cancer. 2005;93:159-166.
14. Crocetti E, Carli P. Risk of second primary cancers, other than melanoma, in an Italian population-based cohort of cutaneous malignant melanoma patients. Eur J Cancer Prev. 2004;1:33-37.
15. Tsao H, Kwitkiwski K, Sober AJ. A single-institution case series of patients with cutaneous melanoma and non-Hodgkin's lymphoma. J Am Acad Dermatol. 2002;46:55-61.
16. Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review 1975-2001. Bethesda, MA: National Cancer Institute; 2004.
17. Abrahamsen AF, Andersen A, Nome O, et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol. 2002;13:1786-1791.
18. Loriot Y, Chaoui D, Dorval T, et al. Association between lymphoma and melanoma: report of a single-center series of eight patients and a review of the literature. Leuk Lymphoma. 2006;47:1023-1028.
19. Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988;318:76-81.
20. Cahill RA, McGreal G, Neary P, et al. Synchronous high-risk melanoma and lymphoid neoplasia. Melanoma Res. 2001;11:517-522.
21. Lens MB, Newton-Bishop JA. An association between cutaneous melanoma and non-Hodgkin's lymphoma: pooled analysis of published data with a review. Ann Oncol. 2005;16:460-465.
22. Said JW, Pinkus GS, Lones MA, et al. Expression of bcl-2 oncogene protein in malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas of T-cell phenotype. Appl Immunohistochem. 1993;1:108-114.
23. Lones MA, Pinkus GS, Shintaku IP, et al. Bcl-2 oncogene is preferentially expressed in Reed-Sternberg cells in Hodgkin's disease of the nodular sclerosis subtype. Am J Clin Pathol. 1994;102:464-467.
24. Grover R, Wilson GD. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur J Surg Oncol. 1996;22:347-349.
25. Cerroni L, Soyer HP, Kerl H. Bcl-2 protein in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol. 1995;17:7-11.
26. Castella A, Mason N, Clarke G, et al. Coexistence of malignant melanoma, Hodgkin's disease and follicular lymphoma with expression of the B-cell leukaemia/lymphoma (bcl-2) oncogene. Histopathology. 1999;35:387-388.